What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?

What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?

What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Michael Ehrenstein, MD

Michael Ehrenstein, MD

Professor of Rheumatology
University College Hospital
University College of London School of Medicine
London, UK